Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Long-Term Investments (2021 - 2026)

C4 Therapeutics has reported Long-Term Investments over the past 6 years, most recently at $32.6 million for Q1 2026.

  • For Q1 2026, Long-Term Investments rose 66.17% year-over-year to $32.6 million; the TTM value through Mar 2026 reached $32.6 million, up 66.17%, while the annual FY2025 figure was $48.6 million, 117.2% up from the prior year.
  • Long-Term Investments for Q1 2026 was $32.6 million at C4 Therapeutics, down from $48.6 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $130.5 million in Q1 2022 and troughed at $7.9 million in Q3 2025.
  • A 5-year average of $40.4 million and a median of $31.6 million in 2024 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: soared 301.53% in 2022 and later plummeted 78.44% in 2023.
  • Year by year, Long-Term Investments stood at $61.0 million in 2022, then tumbled by 54.06% to $28.0 million in 2023, then fell by 20.17% to $22.4 million in 2024, then surged by 117.2% to $48.6 million in 2025, then tumbled by 32.87% to $32.6 million in 2026.
  • Business Quant data shows Long-Term Investments for CCCC at $32.6 million in Q1 2026, $48.6 million in Q4 2025, and $7.9 million in Q3 2025.